E-cadherin breast tumor expression, risk factors and survival : Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium
- Horne, Hisani N.
- Oh, Hannah
- Sherman, Mark E.
- Palakal, Maya
- Hewitt, Stephen M.
- Schmidt, Marjanka K.
- Milne, Roger L.
- Hardisson, David
- Benitez, Javier
- Blomqvist, Carl
- Bolla, Manjeet K.
- Brenner, Hermann
- Chang-Claude, Jenny
- Cora, Renata
- Couch, Fergus J.
- Cuk, Katarina
- Devilee, Peter
- Easton, Douglas F.
- Eccles, Diana M.
- Eilber, Ursula
- Hartikainen, Jaana M.
- Heikkilä, Paivi
- Holleczek, Bernd
- Hooning, Maartje J.
- Jones, Michael
- Keeman, Renske
- Mannermaa, Arto
- Martens, John W. M.
- Muranen, Taru A.
- Nevanlinna, Heli
- Olson, Janet E.
- Orr, Nick
- Perez, Jose I. A.
- Pharoah, Paul D. P.
- Ruddy, Kathryn J.
- Saum, Kai-Uwe
- Schoemaker, Minouk J.
- Seynaeve, Caroline
- Sironen, Reijo
- Smit, Vincent T. H. B. M.
- Swerdlow, Anthony J.
- Tengstrom, Maria
- Thomas, Abigail S.
- Timmermans, A. Mieke
- Tollenaar, Rob A. E. M.
- Troester, Melissa A.
- van Asperen, Christi J.
- van Deurzen, Carolien H. M.
- Van Leeuwen, Flora F.
- Van'tVeer, Laura J.
DOIAbstract
E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, > 2 cm, and HER2-nega...
Add to ORKG